Health Evaluation of Abilify Long-term Therapy

Further study details as provided by Taiwan Otsuka Pharmaceutical Co., Ltd.

Inclusion criteria

• Male or female patients between the ages of 18 to 65.
• Having a DSM-IV diagnosis of schizophrenia or schizoaffective disorder.
• Who are currently taking antipsychotic drugs and clinically intolerable or inadequately controlled that is based upon the clinical judgment of the investigator.

Exclusion criteria

• Pregnant or breast feeding women or planning a pregnancy.
• Patient received electroconvulsive therapy within 4 weeks before the Screening Visit.
• A known allergy reaction to any antipsychotic medication (including but not limited to haloperidol, chlorpromazine, thioridazine, pimozide, risperidone, quetiapine, ziprasidone).
• Patient has clinically relevant organic, neurological, or cardiovascular diseases.
• Patient has a history of drug or alcohol abuse within the last 12 weeks.
• Acute psychosis, acute suicidal ideation, or any acute psychiatric condition that might require emergent intervention.
• Any clinical condition or significant concurrent disease judged by the investigator to complicate the evaluation of the study treatment.
• Having participated other investigational drug study and taken the investigation drug within one month prior to study entry.
• Depot neuroleptics should be discontinued at least 2 months prior to enrollment.